Prostate Cancer
Dosimetric Features of Ultra-Hypofractionated Intensity Modulated Proton Therapy for Prostate Cancer.
June 4, 2024
In vivo genome-wide CRISPR screening identifies CITED2 as a driver of prostate cancer bone metastasis.
May 31, 2024
Unveiling Novel Double-Negative Prostate Cancer Subtypes Through Single-Cell RNA Sequencing Analysis.
May 31, 2024